4889 Stock Overview
Engages in the development and commercialization of pharmaceuticals and medical devices in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Renascience Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥350.00 |
| 52 Week High | JP¥539.00 |
| 52 Week Low | JP¥270.00 |
| Beta | 0.78 |
| 11 Month Change | -1.13% |
| 3 Month Change | 2.34% |
| 1 Year Change | -34.21% |
| 33 Year Change | -55.19% |
| 5 Year Change | n/a |
| Change since IPO | -57.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4889 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -0.3% | 0.2% | 3.6% |
| 1Y | -34.2% | 12.3% | 10.8% |
Return vs Industry: 4889 underperformed the JP Pharmaceuticals industry which returned 12.3% over the past year.
Return vs Market: 4889 underperformed the JP Market which returned 10.8% over the past year.
Price Volatility
| 4889 volatility | |
|---|---|
| 4889 Average Weekly Movement | 10.2% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in JP Market | 10.4% |
| 10% least volatile stocks in JP Market | 3.5% |
Stable Share Price: 4889 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4889's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 4 | Keisuke Furuta | www.renascience.co.jp |
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions.
Renascience Inc. Fundamentals Summary
| 4889 fundamental statistics | |
|---|---|
| Market cap | JP¥4.47b |
| Earnings (TTM) | -JP¥276.00m |
| Revenue (TTM) | JP¥141.00m |
31.6x
P/S Ratio-16.1x
P/E RatioIs 4889 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4889 income statement (TTM) | |
|---|---|
| Revenue | JP¥141.00m |
| Cost of Revenue | JP¥30.00m |
| Gross Profit | JP¥111.00m |
| Other Expenses | JP¥387.00m |
| Earnings | -JP¥276.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 14, 2024
| Earnings per share (EPS) | -21.71 |
| Gross Margin | 78.72% |
| Net Profit Margin | -195.74% |
| Debt/Equity Ratio | 23.0% |
How did 4889 perform over the long term?
See historical performance and comparison